EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer






Strahlentherapie und Onkologie 188(2): 194-195

RTOG study 0324: Cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer



Accession: 055338942

PMID: 22218504

DOI: 10.1007/s00066-011-0034-7



Related references

Blumenschein, G.R.; Paulus, R.; Curran, W.J.; Robert, F.; Fossella, F.; Werner-Wasik, M.; Herbst, R.S.; Doescher, P.O.; Choy, H.; Komaki, R., 2011: Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. Non–small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical models...

Werner-Wasik, M.; Swann, S.; Curran, W.; Robert, F.; Komaki, R.; Lee, C.P.; Jafar, S.; Share, R.; Choy, H.; Blumenschein, G., 2016: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): An interim overall toxicity report of the RTOG 0324 Trial. NlmCategory="UNASSIGNED">7135 Background: Cetuximab (C225) is a chimerized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). NSCLC commonly overexpresses the EGFR, which is associated with aggressive tumor...

R.K.maki; J.M.ughan; K.A.g; W.C.rran Jr.; F.R.bert; J.T.ariat; H.Z.ang; M.W.rner-Wasik; H.C.oy; G.B.umenschein, 2007: RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): Correlation between EGFR expression and the patients' outcome. International Journal of Radiation Oncology*Biology*Physics 69(3-supp-S): 0-0

Blumenschein, G.R.; Paulus, R.; Curran, W.J.; Robert, F.; Fossella, F.V.; Werner-Wasik, M.; Doescher, P.; Choy, H.; Komaki, R., 2016: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): A report of the 2 year and median survival (MS) for the RTOG 0324 trial. NlmCategory="UNASSIGNED">7516 Background: C225 is a chimerized monoclonal antibody that targets the epidermal growth factor receptor (EGFR). NSCLC commonly expresses the EGFR, which is associated with aggressive tumor behavior and poo...

Olsen, C.C.; Paulus, R.; Komaki, R.; Varella-Garcia, M.; Dziadziuszko, R.; Curran, W.J.; Robert, F.; Choy, H.; Blumenschein, G.R.; Hirsch, F.R., 2016: RTOG 0324: A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients with stage IIIA/B non-small cell lung cancer (NSCLC)-Association between EGFR gene copy number and patients' outcome. NlmCategory="UNASSIGNED">7607 Background: C225 in combination with chemotherapy appears promising in first-line therapy for NSCLC. EGFR gene copy number is a predictive outcome marker for treatment with EGFR tyrosine kinase inhibitors...

Anonymous, 2011: Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer RTOG 324. Non–small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical models...

Komaki, R.; Paulus, R.; Blumenschein, G.R.; Curran, W.J.; Robert, F.; Thariat, J.; Werner-Wasik, M.; Choy, H.; Hirsch, F.R.; Ang, K.Kian., 2015: EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: a secondary analysis of RTOG 0324. We investigated whether expression of epidermal growth factor receptor (EGFR) was associated with survival and disease control in this secondary analysis of a phase II trial of cetuximab+chemoradiation for stage III non-small cell lung cancer. Pat...

Bradley, J.D.; Paulus, R.; Komaki, R.; Masters, G.; Blumenschein, G.; Schild, S.; Bogart, J.; Hu, C.; Forster, K.; Magliocco, A.; Kavadi, V.; Garces, Y.I.; Narayan, S.; Iyengar, P.; Robinson, C.; Wynn, R.B.; Koprowski, C.; Meng, J.; Beitler, J.; Gaur, R.; Curran, W.; Choy, H., 2015: Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. We aimed to compare overall survival after standard-dose versus high-dose conformal radiotherapy with concurrent chemotherapy and the addition of cetuximab to concurrent chemoradiation for patients with inoperable stage III non-small-cell lung can...

Coate, L.E.; Gately, K.; Barr, M.P.; Meaney, J.; O'Connell, F.; Nicholson, S.; McGovern, E.; Young, V.; O'Byrne, K., 2016: Phase II pilot study of neoadjuvant cetuximab in combination with cisplatin and gemcitabine in patients with resectable IB-IIIA non small cell lung cancer. NlmCategory="UNASSIGNED">17107 Background: Adjuvant and neoadjuvant chemotherapy play a role in optimising long term outcome of patients with resectable non small cell lung cancer (NSCLC). The epidermal growth factor receptor (EGFR) i...

Werner-Wasik, M.; Langer, C.; Movsas, B., 2005: Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01. While concurrent chemoradiotherapy is a standard treatment for good-performance patients with non-small cell lung cancer, acute esophagitis is a frequent toxicity. The incidence of severe acute esophagitis > or = grade 3 in patients treated wit...